Heska Corporation (NASDAQ:HSKA) Given Daily Media Sentiment Rating of 0.22
Press coverage about Heska Corporation (NASDAQ:HSKA) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Heska Corporation earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 46.3956954976782 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
HSKA has been the topic of several recent analyst reports. Aegis increased their price objective on shares of Heska Corporation from $114.50 to $129.50 and gave the company a “buy” rating in a report on Tuesday, August 1st. B. Riley reaffirmed a “neutral” rating and set a $85.00 price objective on shares of Heska Corporation in a report on Monday, May 8th. BidaskClub downgraded shares of Heska Corporation from a “buy” rating to a “hold” rating in a report on Sunday, July 16th. Zacks Investment Research raised shares of Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 price objective on the stock in a report on Friday, August 4th. Finally, Benchmark Co. reaffirmed a “buy” rating and set a $120.00 price objective (up from $106.00) on shares of Heska Corporation in a report on Wednesday. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $105.20.
Heska Corporation (NASDAQ:HSKA) traded down 0.26% during trading on Friday, reaching $95.64. 31,883 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $101.40 and its 200-day moving average price is $95.86. Heska Corporation has a one year low of $46.51 and a one year high of $115.00. The stock has a market cap of $691.09 million, a P/E ratio of 48.75 and a beta of 0.82.
Heska Corporation (NASDAQ:HSKA) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. Heska Corporation had a net margin of 10.70% and a return on equity of 15.87%. The business had revenue of $34.30 million for the quarter, compared to analyst estimates of $33.35 million. During the same period in the previous year, the firm earned $0.35 EPS. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. On average, equities analysts anticipate that Heska Corporation will post $2.04 earnings per share for the current fiscal year.
In related news, EVP Rod Lippincott sold 11,227 shares of the business’s stock in a transaction dated Wednesday, May 31st. The shares were sold at an average price of $98.00, for a total value of $1,100,246.00. Following the sale, the executive vice president now directly owns 11,292 shares in the company, valued at approximately $1,106,616. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Nancy Wisnewski sold 250 shares of the business’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $100.17, for a total transaction of $25,042.50. Following the completion of the sale, the executive vice president now owns 38,901 shares in the company, valued at $3,896,713.17. The disclosure for this sale can be found here. Insiders sold a total of 30,265 shares of company stock worth $2,983,439 over the last quarter. Insiders own 14.70% of the company’s stock.
About Heska Corporation
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.